CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors

Cell Host and Microbe

Volumn 21, Issue 5, 2017, Pages 580-591.e7

  Ma, Yijie ^a   Walsh, Michael J ^a,b   Bernhardt, Katharina ^a   Ashbaugh, Camille W ^a   Trudeau, Stephen J ^a   Ashbaugh, Isabelle Y ^a   Jiang, Sizun ^a,b   Jiang, Chang ^a   Zhao, Bo ^a   Root, David E ^c   Doench, John G ^c   Gewurz, Benjamin E ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

apoptosis; CRISPR; dependency factor; Epstein Barr virus; gamma herpesvirus; interferon regulatory factor; NF kappaB; oncoprotein; synthetic lethal; tumor virus

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOPTOSIS REGULATORY PROTEIN; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; BATF PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 2; INTERFERON REGULATORY FACTOR-4; IRF2 PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PRDM1 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

APOPTOSIS; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL LINE; CRISPR CAS SYSTEM; DRUG EFFECTS; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; MUTAGENESIS; PHYSIOLOGY; VIROLOGY; VIRUS CELL TRANSFORMATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; B-LYMPHOCYTES; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BURKITT LYMPHOMA; CELL LINE; CELL TRANSFORMATION, VIRAL; COMPLEMENT FACTOR B; CRISPR-CAS SYSTEMS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERON REGULATORY FACTOR-2; INTERFERON REGULATORY FACTORS; MUTAGENESIS; NF-KAPPA B; ONCOGENE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; POSITIVE REGULATORY DOMAIN I-BINDING FACTOR 1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85019072238     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2017.04.005     Document Type: Article

References (77)

1. Anderton, E., Yee, J., Smith, P., Crook, T., White, R.E., Allday, M.J., Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27 (2008), 421–433.
2. Arvey, A., Tempera, I., Tsai, K., Chen, H.S., Tikhmyanova, N., Klichinsky, M., Leslie, C., Lieberman, P.M., An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe 12 (2012), 233–245.
3. Banerjee, S., Lu, J., Cai, Q., Saha, A., Jha, H.C., Dzeng, R.K., Robertson, E.S., The EBV latent antigen 3C inhibits apoptosis through targeted regulation of interferon regulatory factors 4 and 8. PLoS Pathog., 9, 2013, e1003314.
4. Basso, K., Dalla-Favera, R., Roles of BCL6 in normal and transformed germinal center B cells. Immunol. Rev. 247 (2012), 172–183.
5. Bernhardt, K., Haar, J., Tsai, M.H., Poirey, R., Feederle, R., Delecluse, H.J., A viral microRNA cluster regulates the expression of PTEN, p27 and of a bcl-2 homolog. PLoS Pathog., 12, 2016, e1005405.
6. Cahir-McFarland, E.D., Carter, K., Rosenwald, A., Giltnane, J.M., Henrickson, S.E., Staudt, L.M., Kieff, E., Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J. Virol. 78 (2004), 4108–4119.
7. Caldwell, R.G., Wilson, J.B., Anderson, S.J., Longnecker, R., Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9 (1998), 405–411.
8. Caro-Maldonado, A., Wang, R., Nichols, A.G., Kuraoka, M., Milasta, S., Sun, L.D., Gavin, A.L., Abel, E.D., Kelsoe, G., Green, D.R., Rathmell, J.C., Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J. Immunol. 192 (2014), 3626–3636.
9. Cen, O., Longnecker, R., Latent membrane protein 2 (LMP2). Curr. Top. Microbiol. Immunol. 391 (2015), 151–180.
10. Chen, E.Y., Tan, C.M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G.V., Clark, N.R., Ma'ayan, A., Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics, 14, 2013, 128.
11. Cohen, J.I., Fauci, A.S., Varmus, H., Nabel, G.J., Epstein-Barr virus: an important vaccine target for cancer prevention. Sci. Transl. Med., 3, 2011, 107fs7.
12. Dillon, C.P., Oberst, A., Weinlich, R., Janke, L.J., Kang, T.B., Ben-Moshe, T., Mak, T.W., Wallach, D., Green, D.R., Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Rep. 1 (2012), 401–407.
13. Dirmeier, U., Hoffmann, R., Kilger, E., Schultheiss, U., Briseño, C., Gires, O., Kieser, A., Eick, D., Sugden, B., Hammerschmidt, W., Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 24 (2005), 1711–1717.
14. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., Gingeras, T.R., STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29 (2013), 15–21.
15. Doench, J.G., Hartenian, E., Graham, D.B., Tothova, Z., Hegde, M., Smith, I., Sullender, M., Ebert, B.L., Xavier, R.J., Root, D.E., Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 32 (2014), 1262–1267.
16. Doench, J.G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E.W., Donovan, K.F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34 (2016), 184–191.
17. Ernst, J., Kheradpour, P., Mikkelsen, T.S., Shoresh, N., Ward, L.D., Epstein, C.B., Zhang, X., Wang, L., Issner, R., Coyne, M., et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473 (2011), 43–49.
18. Farrell, C.J., Lee, J.M., Shin, E.C., Cebrat, M., Cole, P.A., Hayward, S.D., Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide. Proc. Natl. Acad. Sci. USA 101 (2004), 4625–4630.
19. Feederle, R., Haar, J., Bernhardt, K., Linnstaedt, S.D., Bannert, H., Lips, H., Cullen, B.R., Delecluse, H.J., The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes. J. Virol. 85 (2011), 9801–9810.
20. Forte, E., Luftig, M.A., MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J. Virol. 83 (2009), 2491–2499.
21. Greenfeld, H., Takasaki, K., Walsh, M.J., Ersing, I., Bernhardt, K., Ma, Y., Fu, B., Ashbaugh, C.W., Cabo, J., Mollo, S.B., et al. TRAF1 coordinates polyubiquitin signaling to enhance Epstein-Barr virus LMP1-mediated growth and survival pathway activation. PLoS Pathog., 11, 2015, e1004890.
22. Henderson, S., Rowe, M., Gregory, C., Croom-Carter, D., Wang, F., Longnecker, R., Kieff, E., Rickinson, A., Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65 (1991), 1107–1115.
23. Hulsen, T., de Vlieg, J., Alkema, W., BioVenn—a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics, 9, 2008, 488.
24. Huye, L.E., Ning, S., Kelliher, M., Pagano, J.S., Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination. Mol. Cell. Biol. 27 (2007), 2910–2918.
25. Jha, H.C., Shukla, S.K., Lu, J., Aj, M.P., Banerjee, S., Robertson, E.S., Dissecting the contribution of EBNA3C domains important for EBV-induced B-cell growth and proliferation. Oncotarget 6 (2015), 30115–30129.
26. Jiang, S., Willox, B., Zhou, H., Holthaus, A.M., Wang, A., Shi, T.T., Maruo, S., Kharchenko, P.V., Johannsen, E.C., Kieff, E., Zhao, B., Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A. Proc. Natl. Acad. Sci. USA 111 (2014), 421–426.
27. Johansen, L.M., Deppmann, C.D., Erickson, K.D., Coffin, W.F. 3rd, Thornton, T.M., Humphrey, S.E., Martin, J.M., Taparowsky, E.J., EBNA2 and activated Notch induce expression of BATF. J. Virol. 77 (2003), 6029–6040.
28. Keller, S.A., Hernandez-Hopkins, D., Vider, J., Ponomarev, V., Hyjek, E., Schattner, E.J., Cesarman, E., NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 107 (2006), 3295–3302.
29. Kieff, E., Rickinson, A., Epstein-Barr virus and its replication. Knipe, D.M., Howley, P.M., (eds.) Fields Virology, 2007, Lippincott Williams & Wilkins, 2603–2654.
30. Kuo, T.C., Calame, K.L., B lymphocyte-induced maturation protein (Blimp)-1, IFN regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites. J. Immunol. 173 (2004), 5556–5563.
31. LaCasce, A.S., Post-transplant lymphoproliferative disorders. Oncologist 11 (2006), 674–680.
32. Le, A., Lane, A.N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., Tsukamoto, T., Rojas, C.J., Slusher, B.S., Zhang, H., et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 15 (2012), 110–121.
33. Liao, Y., Smyth, G.K., Shi, W., featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30 (2014), 923–930.
34. Lieberman, P.M., Virology. Epstein-Barr virus turns 50. Science 343 (2014), 1323–1325.
35. Lin, Y., Wong, K., Calame, K., Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 276 (1997), 596–599.
36. Lin, K.I., Lin, Y., Calame, K., Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro. Mol. Cell. Biol. 20 (2000), 8684–8695.
37. Love, M.I., Huber, W., Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 2014, 550.
38. Mancao, C., Hammerschmidt, W., Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 110 (2007), 3715–3721.
39. Mandelbaum, J., Bhagat, G., Tang, H., Mo, T., Brahmachary, M., Shen, Q., Chadburn, A., Rajewsky, K., Tarakhovsky, A., Pasqualucci, L., Dalla-Favera, R., BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 18 (2010), 568–579.
40. Meckes, D.G. Jr., Menaker, N.F., Raab-Traub, N., Epstein-Barr virus LMP1 modulates lipid raft microdomains and the vimentin cytoskeleton for signal transduction and transformation. J. Virol. 87 (2013), 1301–1311.
41. Micheau, O., Thome, M., Schneider, P., Holler, N., Tschopp, J., Nicholson, D.W., Briand, C., Grütter, M.G., The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J. Biol. Chem. 277 (2002), 45162–45171.
42. Milhollen, M.A., Traore, T., Adams-Duffy, J., Thomas, M.P., Berger, A.J., Dang, L., Dick, L.R., Garnsey, J.J., Koenig, E., Langston, S.P., et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-kappaB-dependent lymphoma. Blood 116 (2010), 1515–1523.
43. Minamitani, T., Yasui, T., Ma, Y., Zhou, H., Okuzaki, D., Tsai, C.Y., Sakakibara, S., Gewurz, B.E., Kieff, E., Kikutani, H., Evasion of affinity-based selection in germinal centers by Epstein-Barr virus LMP2A. Proc. Natl. Acad. Sci. USA 112 (2015), 11612–11617.
44. Ning, S., Campos, A.D., Darnay, B.G., Bentz, G.L., Pagano, J.S., TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. Mol. Cell. Biol. 28 (2008), 6536–6546.
45. Nonkwelo, C., Skinner, J., Bell, A., Rickinson, A., Sample, J., Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J. Virol. 70 (1996), 623–627.
46. Nutt, S.L., Hodgkin, P.D., Tarlinton, D.M., Corcoran, L.M., The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15 (2015), 160–171.
47. Paschos, K., Parker, G.A., Watanatanasup, E., White, R.E., Allday, M.J., BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res. 40 (2012), 7233–7246.
48. Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L.H., Lerach, S., Tang, H., Ma, J., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471 (2011), 189–195.
49. Powles, J., Commentary: why diets need to change to avert harm from global warming. Int. J. Epidemiol. 38 (2009), 1141–1142.
50. Price, A.M., Tourigny, J.P., Forte, E., Salinas, R.E., Dave, S.S., Luftig, M.A., Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation. J. Virol. 86 (2012), 11096–11106.
51. Reusch, J.A., Nawandar, D.M., Wright, K.L., Kenney, S.C., Mertz, J.E., Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters. J. Virol. 89 (2015), 1731–1743.
52. Rickinson, A.B., Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin. Cancer Biol. 26 (2014), 99–115.
53. Robertson, E.S., Lin, J., Kieff, E., The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J. Virol. 70 (1996), 3068–3074.
54. Rowe, M., Rowe, D.T., Gregory, C.D., Young, L.S., Farrell, P.J., Rupani, H., Rickinson, A.B., Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6 (1987), 2743–2751.
55. Saha, A., Murakami, M., Kumar, P., Bajaj, B., Sims, K., Robertson, E.S., Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J. Virol. 83 (2009), 4652–4669.
56. Schmidt, S.C., Jiang, S., Zhou, H., Willox, B., Holthaus, A.M., Kharchenko, P.V., Johannsen, E.C., Kieff, E., Zhao, B., Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes. Proc. Natl. Acad. Sci. USA 112 (2015), 554–559.
57. Schmitz, R., Young, R.M., Ceribelli, M., Jhavar, S., Xiao, W., Zhang, M., Wright, G., Shaffer, A.L., Hodson, D.J., Buras, E., et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490 (2012), 116–120.
58. Schmitz, R., Ceribelli, M., Pittaluga, S., Wright, G., Staudt, L.M., Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb. Perspect. Med., 4, 2014, 10.1101/cshperspect.a014282.
59. Seto, E., Moosmann, A., Grömminger, S., Walz, N., Grundhoff, A., Hammerschmidt, W., Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog., 6, 2010, e1001063.
60. Shoham, T., Rajapaksa, R., Boucheix, C., Rubinstein, E., Poe, J.C., Tedder, T.F., Levy, S., The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment. J. Immunol. 171 (2003), 4062–4072.
61. Skalsky, R.L., Corcoran, D.L., Gottwein, E., Frank, C.L., Kang, D., Hafner, M., Nusbaum, J.D., Feederle, R., Delecluse, H.J., Luftig, M.A., et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog., 8, 2012, e1002484.
62. Snow, A.L., Lambert, S.L., Natkunam, Y., Esquivel, C.O., Krams, S.M., Martinez, O.M., EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J. Immunol. 177 (2006), 3283–3293.
63. Song, Y.J., Izumi, K.M., Shinners, N.P., Gewurz, B.E., Kieff, E., IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3. Proc. Natl. Acad. Sci. USA 105 (2008), 18448–18453.
64. Spender, L.C., Cornish, G.H., Rowland, B., Kempkes, B., Farrell, P.J., Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J. Virol. 75 (2001), 3537–3546.
65. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
66. Sugden, B., Epstein-Barr virus: the path from association to causality for a ubiquitous human pathogen. PLoS Biol., 12, 2014, e1001939.
67. Tam, W., Gomez, M., Chadburn, A., Lee, J.W., Chan, W.C., Knowles, D.M., Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 107 (2006), 4090–4100.
68. Tepper, C.G., Seldin, M.F., Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood 94 (1999), 1727–1737.
69. Thorley-Lawson, D.A., Allday, M.J., The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat. Rev. Microbiol. 6 (2008), 913–924.
70. Tuveson, D.A., Carter, R.H., Soltoff, S.P., Fearon, D.T., CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 260 (1993), 986–989.
71. Vrzalikova, K., Vockerodt, M., Leonard, S., Bell, A., Wei, W., Schrader, A., Wright, K.L., Kube, D., Rowe, M., Woodman, C.B., Murray, P.G., Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood 117 (2011), 5907–5917.
72. Weniger, M.A., Küppers, R., NF-κB deregulation in Hodgkin lymphoma. Semin. Cancer Biol. 39 (2016), 32–39.
73. Whyte, W.A., Orlando, D.A., Hnisz, D., Abraham, B.J., Lin, C.Y., Kagey, M.H., Rahl, P.B., Lee, T.I., Young, R.A., Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153 (2013), 307–319.
74. Wood, C.D., Veenstra, H., Khasnis, S., Gunnell, A., Webb, H.M., Shannon-Lowe, C., Andrews, S., Osborne, C.S., West, M.J., MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs. eLife, 5, 2016, 10.7554/eLife.18270.
75. Zhao, B., Marshall, D.R., Sample, C.E., A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jkappa. J. Virol. 70 (1996), 4228–4236.
76. Zhao, B., Barrera, L.A., Ersing, I., Willox, B., Schmidt, S.C., Greenfeld, H., Zhou, H., Mollo, S.B., Shi, T.T., Takasaki, K., et al. The NF-κB genomic landscape in lymphoblastoid B cells. Cell Rep. 8 (2014), 1595–1606.
77. Zhou, H., Schmidt, S.C., Jiang, S., Willox, B., Bernhardt, K., Liang, J., Johannsen, E.C., Kharchenko, P., Gewurz, B.E., Kieff, E., Zhao, B., Epstein-Barr virus oncoprotein super-enhancers control B cell growth. Cell Host Microbe 17 (2015), 205–216.